title: Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
abstract: A new addition to our therapeutic armamentarium against antimicrobial-resistant pathogens is ceftobiprole, a novel broad-spectrum cephalosporin currently undergoing investigation for the treatment of complicated skin and skin structure infections (cSSSIs) and nosocomial pneumonia. Several qualities make ceftobiprole uniquely suited for early empiric use. A major advance from contemporary beta-lactams, ceftobiprole has a high affinity for the altered penicillin-binding protein (PBP) 2' (2a), making it active against methicillin-resistant staphylococci. It also binds avidly to the relevant PBPs of most Gram-positive and Gram-negative pathogens, and is resistant to hydrolysis by many beta-lactamases, making it uniquely suited for infections caused by Gram-positive and mixed Gram-negative organisms. This review summarizes the pharmacokinetic and pharmacodynamic profile of ceftobiprole and addresses in detail the population pharmacokinetic and Monte Carlo simulation analyses used to determine the candidate doses for the cSSSI and nosocomial pneumonia phase 3 clinical trials. This review will also address the ability of the selected dosing regimens in providing adequate free drug concentrations in excess of the MICs against a contemporary group of bacterial isolates from a global resistance surveillance study.
authors.affiliation: Albany College of Pharmacy, Albany, NY 12208, USA. lodiset@acp.edu
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Lodise
authors.forename: Nimish
authors.initials: N
authors.lastname: Patel
authors.forename: Amy
authors.initials: A
authors.lastname: Renaud-Mutart
authors.forename: Evgeny
authors.initials: E
authors.lastname: Gorodecky
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Fritsche
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy; D006801:Humans; D009010:Monte Carlo Method; D011014:Pneumonia / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole